89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control

• 89bio Inc (NASDAQ: ETNB) announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG) at the European Society of Cardiology Congress.

• Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, increasing the risk of coronary artery disease.

• Pegozafermin met its primary endpoint of statistically significant reductions in median triglycerides (TGs) from baseline across all dose groups compared to placebo after eight weeks.

• Related: This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations.

• A sub-study of treated patients showed robust reductions in liver fat from baseline at week eight across all dose groups versus placebo.

• Further, 88% of treated patients vs. 0% of placebo patients achieved a ≥30% reduction in liver fat from baseline, and 24% of treated patients vs. 0% of placebo patients achieved normalized liver fat levels at week 8.

• Pegozafermin treatment also resulted in clinically meaningful improvements in non-HDL-C and apo-B, a key marker of cardiovascular risk and a direct measure of the number of atherogenic particles.

• Pegozafermin is currently being evaluated in the Phase 2b ENLIVEN trial in NASH and is expected to move into the Phase 3 program for SHTG in 2023.

• Price Action: ETNB shares are up 7.61% at $5.10 during the premarket session on the last check Friday.

See more from Benzinga

• Analysts Are Bullish On 89bio's NASH Data Slated For Early Next Year

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.